Remove 2026 Remove Biosimilars Remove Diabetes
article thumbnail

STAT+: Pharmalittle: We’re reading about Amylyx pulling its ALS drug, GLP-1 drugs for Parkinson’s, and more

STAT

… The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, such as mental health disorders, Alzheimer’s, and even, as new study results suggest — Parkinson’s disease , STAT writes.  In

Diabetes 275
article thumbnail

Obesity drug tirzepatide approval in China strengthens market position amid GLP-1 agonist competition: GlobalData

Express Pharma

Benemae Pharmaceutical’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisk’s diabetes therapy semaglutide (Wegovy) in June 2024. The global obesity market faces supply issues, prompting Chinese pharma companies to leverage the situation to develop GLP-1 biosimilars.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grail plans FDA filing for cancer blood test after new trial

pharmaphorum

Skip to main content Friday 20 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

NHC Submits Comments to CMS RE CY 2026 Policy & Technical Changes to MA and Part D Proposed Rule

Putting Patients First Blog

The NHC recognizes that Medicare already covers AOMs for patients who are overweight and have comorbid conditions such as diabetes or cardiovascular disease. To further strengthen these efforts, the NHC recommends that CMS adopt additional measures to ensure broad access to generics, biosimilars, and other cost-effective treatments.

article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

CMS should draw on lessons from previous transitions, including biosimilar coverage rollouts and site-of-care policy shifts, to avoid known implementation pitfalls. These materials should be made available in multiple formats and languages and cover billing practices, coinsurance changes, and patient rights in plain language. July 2, 2024.

article thumbnail

Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product

Pharmacy Times

The study's primary objective was to assess reversion rates to Humira, with 9% reverting after three months, while 91% remained on biosimilars or switched to alternatives. SHOW MORE Real-world data shows patients switching from Humira to biosimilars Hadlima and Hyrimoz achieve similar outcomes without hospitalization.